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ABSTRACT
Introduction: An important determinant of the effectiveness of HIV treatment programs is the capacity of sites to implement
recommended services and identify systematic changes needed to ensure that invested resources translate into improved
patient outcomes. We conducted a survey in 2014 of HIV care and treatment sites in the seven regions of the International
epidemiologic Database to Evaluate AIDS (IeDEA) Consortium to evaluate facility characteristics, HIV prevention, care and
treatment services provided, laboratory capacity, and trends in the comprehensiveness of care compared to data obtained in
the 2009 baseline survey.
Methods: Clinical staff from 262 treatment sites in 45 countries in IeDEA completed a site survey from September 2014 to
January 2015, including Asia-Pacific with Australia (n = 50), Latin America and the Caribbean (n = 11), North America (n = 45),
Central Africa (n = 17), East Africa (n = 36), Southern Africa (n = 87), and West Africa (n = 16). For the 55 sites with complete
data from both the 2009 and 2014 survey, we evaluated change in comprehensiveness of care.
Results: The majority of the 262 sites (61%) offered seven essential services (ART adherence, nutritional support, PMTCT,
CD4+ cell count testing, tuberculosis screening, HIV prevention, and outreach). Sites that were publicly funded (64%), cared
for adults and children (68%), low or middle Human Development Index (HDI) rank (68%, 68%), and received PEPFAR support
(71%) were most often fully comprehensive. CD4+ cell count testing was universally available (98%) but only 62% of clinics
offered it onsite. Approximately two-thirds (69%) of sites reported routine viral load testing (44–100%), with 39% having it
onsite. Laboratory capacity to monitor antiretroviral-related toxicity and diagnose opportunistic infections varied widely by
testing modality and region. In the subgroup of 55 sites with two surveys, comprehensiveness of services provided
significantly increased across all regions from 2009 to 2014 (5.7 to 6.5, p < 0.001).
Conclusions: The availability of viral load monitoring remains suboptimal and should be a focus for site capacity, particularly in
East and Southern Africa, where the majority of those initiating on ART reside. However, the comprehensiveness of care provided
increased over the past 5 years and was related to type of funding received (publicly funded and PEPFAR supported).
Keywords: HIV; HIV care capacity; comprehensive care; survey; laboratory capacity; resource-limited settings;
implementation science
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Introduction
Over the past five years, significant progress has been made
towards increasing individual access to potentially life-sav-
ing combination antiretroviral therapy (ART), which has led
to reductions in HIV-associated morbidity and mortality. As
a result, there were 15.8 million people on ART by mid-
2015 [1]. These gains towards the goal of universal access
to HIV treatment do not come without challenges.
Developing a sustainable way to provide lifelong ART and
monitor the impact on local health systems is critical.
Likewise, identifying specific barriers to HIV diagnosis and
treatment that persist in different regions is necessary. In
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order to achieve these goals, an understanding of the
current state of HIV care delivery is essential.
Studies focused on site characteristics have identified
gaps in care delivery and program components associated
with better patient outcomes [2–11]. For instance, adher-
ence support services, active patient outreach, and food
rations are associated with improved retention in care after
ART initiation [6]. Thus, site-level analyses play an invalu-
able role in identifying systematic changes needed to
ensure that resources are invested in HIV program compo-
nents that have been associated with improved patient
outcomes.
In 2009, the International epidemiologic Database to
Evaluate AIDS (IeDEA) Consortium developed and imple-
mented a baseline site assessment (referred to as Site
Assessment 1.0; “SA 1.0”) to characterize facility and pro-
grammatic attributes, contextual factors, and clinical-level
procedures for HIV care sites within the consortium. The
survey also aimed to evaluate the capacity to deliver com-
prehensive World Health Organization (WHO)-recom-
mended HIV prevention, care, and treatment services
[12]. Analysis of the survey showed significant variation in
program characteristics and the capacity to deliver recom-
mended comprehensive HIV services across geographic
regions [13]. Sites located in low-HDI settings that received
United States President’s Emergency Plan for AIDS Relief
(PEPFAR) support offered a more comprehensive array of
the 7 essential services studied than sites in middle or high-
HDI settings and sites in low-HDI settings not receiving
PEPFAR support. This study was intended to serve as a
baseline for monitoring care delivery over time.
Since 2009, there have been both policy and techno-
logical advances within the field of HIV treatment. The
2013 WHO consolidated guidelines recommended routine
viral load monitoring as the preferred method to screen
for ART treatment failure [14]. Additionally, new modal-
ities for early and accurate diagnosis of opportunistic
infections (OIs) such as GeneXpert MTB/RIF™ for tuber-
culosis [15–17] and cryptococcal antigen lateral flow
assay [18–20] for the detection of cryptococcal meningi-
tis have become available [21–23]. Finally, PEPFAR has
increasingly supported sustainability and country owner-
ship of programs so that select countries now receive
less external donor support [24,25].
We conducted a survey in 2014 to evaluate the current
capacity of IeDEA sites to deliver the most recent WHO-
recommended HIV prevention, care, and treatment ser-
vices. In this analysis, we assessed the comprehensive-
ness of HIV services provided within IeDEA in 2014,
described laboratory capacity for ART monitoring and
diagnosis of select OIs, and compared trends in ability
to deliver comprehensive services across sites from 2009
to 2014. We hypothesized that comprehensiveness of
services would continue to vary by region, that decreases
in PEPFAR support would result in decreased comprehen-
siveness, and that only a small proportion of sites in low-
and middle-income countries (LMIC) would have capacity
to measure viral load.
Methods
IeDEA is a global research consortium of HIV care and treat-
ment sites in seven geographic regions: Central Africa, East
Africa, South Africa, West Africa, the Caribbean, Central, and
South America (CCASAnet), Asia-Pacific (including Australia),
and North America [26–30]. IeDEA is funded to collect glob-
ally diverse data to address key clinical and operational
questions that cannot be answered by a cohort of patients
in a single geographical location.
Survey development
IeDEA investigators developed a 40-item site survey to col-
lect information on characteristics of each participating site
including: facility information (location, funding, academic
affiliation, patient population); clinic staffing; prevention ser-
vices (HIV counselling and testing, family planning, education
on risk behaviour, prevention of mother-to-child transmis-
sion (PMTCT) of HIV); clinical services offered (blood pres-
sure monitoring, diabetic screening, OI screening and
treatment, co-trimoxazole prophylaxis); access to laboratory
testing (CD4+ cell count, HIV viral load, sexually transmitted
infection (STI) screening, hepatitis B/C testing, TB diagnosis,
antiretroviral (ARV)-related toxicity screening (i.e. haemoglo-
bin, creatinine, AST/ALT)); ART adherence support and out-
reach programs (counselling, short message service (SMS)
reminders, patient tracking); pharmacy capacity (medications
dispensed, frequency of stock outs, ART waitlists); nutritional
services (counselling, micronutrient assessment and supple-
mentation, food supplementation); specific paediatric ser-
vices, and ability to screen for and/or treat cancer. Location
was identified by the site representative selecting “Urban,
Mostly Urban, Mostly Rural, Rural, or Unknown” in response
to the question “What is the location of this site”.
English (Additional file 1) and French versions of the
survey were distributed online and in paper form.
REDCap, a secure web-based application designed to sup-
port data collection for research studies [31], was used to
implement the online version of the survey.
Data collection
All seven IeDEA regions agreed to participate in SA 2.0.
Data managers from each region distributed a link to the
web-based survey as well as a PDF of the paper-based
survey to a designated clinical staff member for each
IeDEA clinic or cohort of clinics in their region. Paper
surveys were entered into REDCap and accuracy of data
input was verified by the regional data team.
The site assessment was conducted in all IeDEA regions
between September 2014 and January 2015. In order to
ensure completeness of data, a team at the IeDEA Network
Coordinating Center (INCC) at Vanderbilt worked with regio-
nal data managers after the survey closed to query sites
regarding incomplete questions. The sites and coordinating
centres for all regions had Institutional Review Board
approvals in place permitting the collection of site-level
data for this site assessment survey. This study was approved
by the Vanderbilt University Internal Review Board as
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nonhuman subject research (IRB number 141851) because
only site-level (not patient-level) data were collected.
Comprehensiveness
We used a previously developed comprehensiveness metric
that provides a score of one to seven to describe the
availability of seven essential WHO-recommended HIV
care services for adults and adolescents at IeDEA sites in
2014 [13]. The services included: ART adherence, nutri-
tional support, PMTCT provision, CD4+ cell count testing,
TB screening, prevention services, and community outreach
(Table 1). We also created a “comprehensiveness plus”
variable that counts availability of both viral load monitor-
ing and CD4+ cell count monitoring as one of seven essen-
tial services, as compared to availability of CD4+ cell count
monitoring alone. Each clinic that completed all necessary
survey questions was assigned a comprehensiveness score
ranging from three to seven.
Sites were grouped into comprehensiveness categories
derived from examination of data distribution of low (3–5
services), medium (6 services), or high (all seven services).
We assessed the availability of essential services by region
and site characteristics including type of patients (adults
only v. adults and children), funding (public v. private),
facility level (primary, secondary, tertiary), academic affilia-
tion (affiliation v. no affiliation), PEPFAR support in 2014
(support provided v. no support provided), and country
rank on the 2014 UN Human Development Index (HDI)
(low, middle, high) [32]. We also evaluated change in com-
prehensiveness of care available from 2009 to 2014 by
comparing sites that (1) completed both SA 1.0 and SA
2.0 and (2) answered all survey questions necessary to
assign a comprehensiveness score.
Statistical analysis
Data from English and French surveys were merged in
REDCap and exported for analysis. The data were cleaned
and analyzed using Stata version 13 (www.stata.com) and
R-software 3.2.0 (www.r-project.org). Sites seeing solely
paediatric patients or missing data on site characteristics
were excluded from all analyses. An alpha of <0.01 was
used to define statistical significance in all tests conducted.
Analyses of 2014 data included descriptive statistics and
frequency calculations. Frequencies of site characteristic
variables were stratified by region. The distribution of com-
prehensiveness score (low, medium, or high) and “compre-
hensiveness plus” score was examined by site characteristic
and region. Frequency of availability of each essential ser-
vice was also calculated. Statistical significance was deter-
mined using a Chi-squared test. Frequency of availability of
laboratory testing was stratified by region. A paired
Wilcoxon test was used to compare comprehensiveness
across SA 1.0 and 2.0. One-way ANOVA F-tests were used
to determine associations between site characteristics and
change in comprehensiveness score from SA 1.0 to SA 2.0.
Results
Site overview
Of the 536 sites initially approached with the SA 2.0 survey,
249 (46%) did not meet eligibility criteria, most commonly
because the site was an interval cohort (contributing data
but no longer a clinical site) (N = 139) or was no longer an
active site (N = 36) (Supplemental Table 1). Among the 287
HIV care and treatment sites within IeDEA that were eligi-
ble and completed the survey, 24 sites (8%) that only
provided care for children and 1 site (<1%) missing informa-
tion on service population were excluded from analyses.
The remaining 262 sites (91% of sites responding to the
survey) were included for analysis. The number of sites
included in the analysis varied by region, from 11 in
CCASAnet to 87 in Southern Africa (Table 2).
The majority of clinics reported being located in an urban
setting (67%), (Table 2). This pattern was true for all regions
Table 1. Comprehensiveness variable definitions
Variable Definition
ART adherence Providing one-on-one counselling, calendar and checklist reminders, and routine review of
medication pickup
Nutritional support Counselling, nutritional assessment, micronutrient/vitamin supplements or food supplement
Prevention of mother-to-child
transmission (PMTCT)
PMTCT provision onsite or at the same facility
CD4+ cell count testing Testing onsite or offsite
TB screening Clinical symptoms and acid-fast bacilli (AFB) smear onsite or in the same health facility
Prevention services HIV testing and counselling and one or more of the following: disclosure counselling to sexual
partners, education on safe sex methods, family planning counselling, provision of condoms,
provision of other birth control methods, education on high-risk substance-use behaviours,
screening for drug and alcohol use/abuse, referral for substance abuse treatment, pre-exposure
prophylaxis, and post-exposure prophylaxis
Outreach Community outreach to track patients taking ART who miss an appointment
CD4+ Cell count + Viral load testing Testing onsite or offsite
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with the exception of East Africa, where 42% of clinics were
located in a rural setting and 25% were urban. Most sites
were publicly funded (87%), and 46% of sites reported
affiliation with an academic institution. Overall, sites were
most often located within a primary (42%) or tertiary (40%)
care centre. This varied by region, with 100% of sites
located in tertiary facilities in Central Africa and CCASAnet
while the majority of sites in Southern Africa (63%) and
Asia-Pacific (54%) were primary-level facilities.
Comprehensiveness
Comprehensiveness measures were calculated for the 260
(99%) sites having completed all survey questions required
to calculate a score. Comprehensiveness scores ranged
from 3 to 7, the mean (standard deviation (SD)) was 6.3
(0.9) and the median (interquartile range) was 7 (6–7).
Twenty-five of the 260 sites (10%) offered 3–5 essential
services (low); 77 sites (30%) offered six essential services
(medium), and 158 (61%) sites offered all seven essential
services (high). All sites offered HIV prevention counselling
and testing as well as at least one additional prevention
service (Table 3). Measures to ensure ART adherence (96%),
CD4+ cell count testing onsite or at the same health facility
(98%), PMTCT (97%), and outreach programs to track
patients on ART (91%) were also commonly available.
Nutritional support and TB screening were the services
most often lacking at 78% and 88%, respectively. Both CD
+ cell count and viral load testing were offered routinely at
68% of sites.
Table 4 summarizes the characteristics of facilities by
level of comprehensiveness. Comprehensiveness varied
significantly by region (p < 0.001), type of patients seen
(<0.001), facility type (p = 0.005), PEPFAR support
(p < 0.001), and UN HDI rank (p = 0.005). Sites in East
Africa and Southern Africa had the highest percentage
of sites offering all seven services (89% and 72%,
respectively). Sites seeing adults and children were
more frequently fully comprehensive than sites seeing
only adults (68% v. 43%). The majority of public sites
(64%) and sites receiving PEPFAR support (71%) were
fully comprehensive (high level). Of sites in high-ranked
countries according to 2014 UN HDI ranking, 48% were
fully comprehensive as compared to those located in
medium and low-ranked countries of which 68% and
68%, respectively, were fully comprehensive.
Analysis of the “Comprehensiveness plus” metric across
260 sites revealed a lower proportion of fully comprehen-
sive sites (61% v. 39% in “Comprehensiveness Plus”)
(Table 5). East and Southern Africa remained the regions
that most commonly offered all services, however, a smal-
ler proportion of sites within each region were fully com-
prehensive (89% v. 78% and 72% v. 55%, respectively). The
majority of sites that care for adults and children (58%),
publicly funded sites (55%), sites with PEPFAR support
(60%), and countries with low HDI rank (62%) were fully
comprehensive
Availability of laboratory services
Of the 262 sites completing the survey, only two sites (1%)
reported not using CD4+ cell count testing to monitor
immunologic status of HIV patients. Such testing was used
routinely at 90% of sites and offered onsite at the majority
of clinics (62%), (Table 6). Onsite CD4+ cell count testing
was least commonly available in Central Africa (31%), fol-
lowed by Southern Africa (53%) and East Africa (53%). The
majority of sites reported availability of viral load monitor-
ing (89%), although only 69% of sites had viral load routi-
nely available. Routine viral load monitoring was
infrequently available for patient care monitoring in West
Africa (44% of sites) and Southern Africa (41%), compared
to Central and East Africa where it was used routinely in
76% and 72% of sites, respectively. On or offsite, HIV-1 drug
resistance testing was not frequently available to the clin-
ical staff (42%), except in North America (96%) and Asia-
Pacific (88%).
The availability of laboratory monitoring for ARV medica-
tion-related toxicities across 262 sites varied by laboratory
test and by region (Table 7). Haemoglobin testing was
uniformly available (98%) across all regions, though the
survey did not specify if this testing was done onsite or
offsite. The majority of labs were also capable of perform-
ing serum creatinine (76%), AST and/or ALT (73%), and
diabetic screening (68%). However, serum cholesterol
(55%) and triglyceride (54%) measurement were less fre-
quently available.
Among 262 included sites, capacity for diagnosis of OIs
remains low (Table 8). The ability to diagnose TB varied
by testing modality used. Specifically, TB diagnosis by
sputum AFB smear was routinely available in the clinic
or the same health facility (89%) while TB culture was
available onsite for only 47% of sites. The newer diag-
nostic modality GeneXpert MTB/RIF™ (40%) and TB drug
resistance testing (33%) were infrequently available
onsite (in the clinic or the same health facility).
Similarly, screening for cryptococcal meningitis was not
routinely available. However, screening using serum cryp-
tococcal antigen (47%) and cerebral spinal fluid (CSF)
India ink or CSF antigen (42%) was more widely available
than the newer lateral flow assay (29%).
Table 3. Distribution of services in the IeDEA global consor-
tium, 2014
Offered, N Offered, %
ART adherence support services 250 96%
Nutritional support 204 78%
PMTCT 251 97%
CD4+ cell count testing 256 98%
TB screening 230 88%
HIV prevention 260 100%
Outreach 237 91%
*CD4+ cell count and viral load testing 228 88%
*Used for calculation of “Comprehensiveness Plus”.
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Trends in comprehensiveness of HIV prevention, care, and
treatment
We compared comprehensiveness level in 2014 to that in
2009 for the 55 sites (19%) with complete comprehen-
siveness data for both surveys (Table 9). Of note, a
comprehensiveness score could not be computed for
Southern Africa in 2009 because they did not contribute
site-level data to SA 1.0. There was a significant increase
in the comprehensiveness score across all regions from
2009 to 2014 (p < 0.001). The per cent of sites offering
nutritional support and outreach services notably
increased with smaller increases in availability of PMTCT
and TB screening (Table 10).
Table 4. Comprehensiveness of HIV care and treatment services, IeDEA global consortium, 2014
Low (3–5) Medium (6) High (7) All sites p-value
(n = 25) (n = 77) (n = 158) (n = 260)
Region, n (%) <0.001
Central Africa 3 (18%) 6 (35%) 8 (47%) 17 (7%)
East Africa 0 (0%) 4 (11%) 32 (89%) 36 (14%)
Southern Africa 2 (2%) 22 (25%) 63 (72%) 87 (33%)
West Africa 2 (13%) 8 (50%) 6 (38%) 16 (6%)
CCASAnet 4 (36%) 3 (27%) 4 (36%) 11 (4%)
Asia Pacific 10 (20%) 17 (34%) 23 (46%) 50 (19%)
North America 4 (9%) 17 (40%) 22 (51%) 43 (17%)
All Regions 25 (10%) 77 (30%) 158 (61%) 260
Patients seen, n (%) <0.001
Adults only 12 (16%) 31 (41%) 33 (43%) 76 (29%)
Both adults and children 13 (7%) 46 (25%) 125 (68%) 184 (71%)
Site location, n (%) 0.20
Mostly rural 0 (0%) 6 (40%) 9 (60%) 15 (6%)
Mostly urban 3 (13%) 5 (21%) 16 (67%) 24 (9%)
Rural 2 (4%) 10 (21%) 35 (74%) 47 (18%)
Urban 20 (11%) 56 (32%) 98 (56%) 174 (67%)
Type of facility, n (%) 0.005
Private 8 (24%) 12 (35%) 14 (41%) 34 (13%)
Public 17 (8%) 65 (29%) 144 (64%) 226 (87%)
Academic affiliation, n (%) 0.65
No 13 (9%) 38 (27%) 89 (64%) 140 (54%)
Yes 12 (10%) 38 (32%) 69 (58%) 119 (46%)
Missing 0 1 0 1
Level of facility, n (%) 0.013
Primary 13 (12%) 30 (28%) 65 (60%) 108 (42%)
Secondary 0 (0%) 9 (19%) 38 (81%) 47 (18%)
Tertiary 11 (11%) 37 (36%) 55 (53%) 103 (40%)
Missing 1 1 0 2
Country PEPFAR-support status (2014), n (%) <0.001
No PEPFAR 19 (19%) 36 (37%) 43 (44%) 98 (38%)
PEPFAR 6 (4%) 40 (25%) 115 (71%) 161 (62%)
Missing 0 1 0 1
UN Health Development Index [32], n (%) 0.005
UN HDI low rank 5 (6%) 21 (26%) 55 (68%) 81 (31%)
UN HDI middle rank 4 (5%) 24 (27%) 60 (68%) 88 (34%)
UN HDI high rank 16 (18%) 31 (34%) 43 (48%) 90 (35%)
Missing 0 1 0 1
Percentages are computed using the number of sites with a non-missing value.
Two-sided p-value from chi-square test. p-value calculation does not include missing values.
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Discussion
This survey provides an update on the HIV prevention
and treatment services available at a diverse cohort of
sites within the global IeDEA consortium. We found that
comprehensiveness of care provided varied by region,
patients seen, site funding, UN HDI category, and pre-
sence of PEPFAR support. Similar to the baseline assess-
ment [13], sites receiving PEPFAR support offer more
comprehensive services than sites without PEPFAR sup-
port. Likewise, sites in low- and middle-HDI countries
Table 5. “Comprehensiveness plus” of HIV care and treatment services, IeDEA global consortium, 2014
Low (3–5) Medium (6) High (7) All Sites
(n = 33) (n = 88) (n = 139) (n = 260) p-value
Region n (%) 0.051
Central Africa 3 (18%) 6 (35%) 8 (47%) 17 (7%)
East Africa 1 (3%) 7 (19%) 28 (78%) 36 (14%)
Southern Africa 9 (10%) 30 (34%) 48 (55%) 87 (33%)
West Africa 2 (13%) 8 (50%) 6 (38%) 16 (6%)
CCASAnet 4 (36%) 3 (27%) 4 (36%) 11 (4%)
Asia-Pacific 10 (20%) 17 (34%) 23 (46%) 50 (19%)
North America 4 (9%) 17 (40%) 22 (51%) 43 (17%)
All regions 46 (18%) 112 (43%) 102 (39%) 260
Patients seen, n (%) 0.11
Adults only 12 (16%) 31 (41%) 33 (43%) 76 (29%)
Both adults and children 21 (11%) 57 (31%) 106 (58%) 184 (71%)
Site location, n (%) 0.94
Mostly rural 1 (7%) 6 (40%) 8 (53%) 15 (6%)
Mostly urban 3 (13%) 6 (25%) 15 (63%) 24 (9%)
Rural 6 (13%) 15 (32%) 26 (55%) 47 (18%)
Urban 23 (13%) 61 (35%) 90 (52%) 174 (67%)
Type of facility, n (%) 0.030
Private 9 (26%) 11 (32%) 14 (41%) 34 (13%)
Public 24 (11%) 77 (34%) 125 (55%) 226 (87%)
Academic affiliation, n (%) 0.34
No 21 (15%) 49 (35%) 70 (50%) 140 (54%)
Yes 12 (10%) 38 (32%) 69 (58%) 119 (46%)
Missing 0 1 0 1
Level of facility, n (%) 0.13
Primary 18 (17%) 36 (33%) 54 (50%) 108 (42%)
Secondary 2 (4%) 13 (28%) 32 (68%) 47 (18%)
Tertiary 12 (12%) 38 (37%) 53 (51%) 103 (40%)
Missing 1 1 0 2
Country PEPFAR-support status (2014), n (%) 0.013
No PEPFAR 19 (19%) 36 (37%) 43 (44%) 98 (38%)
PEPFAR 14 (9%) 51 (32%) 96 (60%) 161 (62%)
Missing 0 1 0 1
UN Health Development Index, n (%) 0.25
UN HDI low rank 8 (10%) 23 (28%) 50 (62%) 81 (31%)
UN HDI middle rank 9 (10%) 33 (38%) 46 (52%) 88 (34%)
UN HDI high rank 16 (18%) 31 (34%) 43 (48%) 90 (35%)
Missing 0 1 0 1
Percentages are computed using the number of sites with a non-missing value.
Two-sided p-value from chi-square test. p-value calculation does not include missing values.
The mean (SD) of comprehensiveness score is 6.2 4 (0.8). The median (IQR) of comprehensiveness score is 6 7 (6–7). The range
of comprehensiveness score is 3 (4–7).
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offered more comprehensive services than those in high-
HDI countries. Additionally, sites serving adults and chil-
dren and publicly funded sites were more comprehensive.
These results suggest that PEPFAR funding continues to
play an important role in delivering essential HIV services
to resource-limited settings. Efforts to further increase
comprehensiveness can focus on providing TB screening,
nutritional support, and routine viral load testing, which
were the essential services least often available.
Formal comparison of 2009 and 2014 survey data
revealed an overall increase of about one additional point
in the comprehensiveness score, which is equivalent to
Table 6. Use of CD4+ cell count and viral load monitoring, HIV care and treatment sites, IeDEA global consortium, 2014
Central
Africa
East
Africa
Southern
Africa
West
Africa
CCASA
net
Asia-
Pacific
North
America Combined
(n = 17) (n = 36) (n = 87) (n = 16) (n = 11) (n = 50) (n = 45) (n = 262)
Rapid HIV testing 16 (94%) 33 (92%) 69 (79%) 16 (100%) 9 (82%) 37 (74%) 33 (73%) 213 (81%)
Monitoring with CD4 testing, n (%)
Yes, routinely 14 (82%) 26 (72%) 80 (92%) 14 (88%) 9 (82%) 47 (94%) 44 (100%) 234 (90%)
Yes, but not routinely 3 (18%) 10 (28%) 5 (6%) 2 (12%) 2 (18%) 3 (6%) 0 (0%) 25 (10%)
No, not available 0 (0%) 0 (0%) 2 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (1%)
Missing 0 0 0 0 0 0 1 1 (<1%)
CD4 testing location, n (%)
Onsite, at same health facility 5 (31%) 19 (53%) 45 (53%) 13 (81%) 10 (91%) 34 (68%) 35 (80%) 161 (62%)
Offsite, at a distance 11 (69%) 17 (47%) 40 (47%) 3 (19%) 1 (9%) 16 (32%) 9 (20%) 97 (38%)
Missing 1 0 2 0 0 0 1 4
Monitoring with viral load testing, n (%)
Yes, routinely 13 (76%) 26 (72%) 36 (41%) 7 (44%) 8 (73%) 45 (90%) 45 (100%) 180 (69%)
Yes, but not routinely 4 (24%) 5 (14%) 27 (31%) 8 (50%) 3 (27%) 5 (10%) 0 (0%) 52 (20%)
No, not available 0 (0%) 5 (14%) 24 (28%) 1 (6%) 0 (0%) 0 (0%) 0 (0%) 30 (11%)
Viral load testing location, n (%)
Onsite, at same health facility 2 (12%) 4 (13%) 9 (14%) 8 (53%) 8 (73%) 29 (58%) 30 (67%) 90 (39%)
Offsite, at a distance 15 (88%) 27 (87%) 54 (86%) 7 (47%) 3 (27%) 21 (42%) 15 (33%) 142 (61%)
Missing 0 5 24 1 0 0 0 30
*HIV-1 genotypic drug resistance testing 0 (0%) 3 (8%) 8 (9%) 5 (31%) 7 (64%) 44 (88%) 43 (96%) 110 (42%)
Percentages are computed using the number of sites with a non-missing value.
* Method of testing used not collected in survey.
Table 7. Availability of laboratory testing for toxicity monitoring and non-communicable disease screening, HIV care and
treatment sites, IeDEA global consortium, 2014
Central
Africa
East
Africa
Southern
Africa
West
Africa
CCASA
net
Asia-
Pacific
North
America Combined
(n = 17) (n = 36) (n = 87) (n = 16) (n = 11) (n = 50) (n = 45) (n = 262)
Haemoglobin 16 (94%) 36 (100%) 85 (98%) 16 (100%) 11 (100%) 50 (100%) 45 (100%) 259 (98%)
Creatinine 13 (76%) 22 (61%) 46 (53%) 15 (94%) 11 (100%) 49 (98%) 45 (100%) 201 (76%)
Serum cholesterol 9 (53%) 5 (14%) 22 (25%) 6 (38%) 9 (82%) 49 (98%) 45 (100%) 145 (55%)
Triglycerides 9 (53%) 4 (11%) 19 (22%) 6 (38%) 10 (91%) 49 (98%) 45 (100%) 142 (54%)
AST (SGOT) and/or ALT
(SGPT)
13 (76%) 17 (47%) 42 (48%) 14 (88%) 11 (100%) 49 (98%) 45 (100%) 191 (73%)
Diabetic screening 14 (82%) 17 (47%) 44 (51%) 11 (69%) 9 (82%) 41 (82%) 44 (98%) 180 (68%)
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provision of one additional essential service. Provision of
nutritional support and outreach services increased most
notably with smaller increases in availability of PMTCT and
TB screening. Prevention, ART adherence services, and CD4
+ cell count testing remained routinely available.
Interestingly, there has also been an increase in the services
provided at clinics in high HDI countries which may suggest
a shift towards a public health-focused central provision of
essential HIV services in resource-replete countries.
This survey also provides valuable insight into the use of
monitoring laboratory tests essential for providing effective
HIV care. The majority of sites in IeDEA report using CD4+
cell count routinely for monitoring patients on ART while
viral load monitoring was used less routinely. Both tests are
less commonly available onsite in resource-limited settings.
This is problematic because requiring patients to travel to
an offsite facility for testing introduces an additional step
where return of results is delayed, samples may be lost, or
patients may be lost to follow up [33–35]. High cost, tech-
nical complexity, and quality control have been identified as
barriers significantly limiting its availability in resource-con-
strained settings [36–38]. Routine viral load monitoring can
identify patients in need of increased adherence support to
achieve viral suppression and its associated individual and
public health benefit and reduce the development of drug
resistance [39]. Thus, there is a need to focus on the
development of point-of-care viral load testing as well as
augmentation of supply chains to support decentralization
of viral load testing.
Another important laboratory service is the ability to
monitor for ARV-related toxicities such as anaemia, hepa-
totoxicity, and renal insufficiency. Patients with HIV, espe-
cially those on ART, are also at a higher risk of developing
non-communicable diseases (NCDs) such as cardiovascu-
lar, metabolic, renal, and hepatic diseases [40–42]. NCDs
are an increasing issue in LMICs, which now account for
90% of global NCD-related deaths that occur before the
age of 60 [43]. Despite the evident need for such tests,
we found that serum cholesterol and triglyceride mea-
surement were rarely available at African sites. There are
limited data available on the ability of LMICs to diagnose
and manage NCDs [44]; more research in this area is
needed. Additionally, augmenting the infrastructure and
funding needed to monitor and treat such diseases is
imperative to prevent NCD-related morbidity and
mortality.
Table 8. Availability of OI screening/diagnosis, global HIV care and treatment sites, IeDEA global consortium, 2014
Central
Africa
East
Africa
Southern
Africa
West
Africa
CCASA
net
Asia-
Pacific
North
America Combined
(n = 17) (n = 36) (n = 87) (n = 16) (n = 11) (n = 50) (n = 45) (n = 262)
TB diagnosis (AFB smear), n (%)
In this clinic 8 (47%) 26 (72%) 38 (44%) 10 (62%) 9 (82%) 35 (70%) 30 (67%) 156 (60%)
Same facility 4 (24%) 8 (22%) 39 (45%) 3 (19%) 2 (18%) 9 (18%) 11 (24%) 76 (29%)
Only off site 5 (29%) 2 (6%) 10 (11%) 3 (19%) 0 (0%) 6 (12%) 3 (7%) 29 (11%)
Not available 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (2%) 1 (< 1%)
TB diagnosis (culture), n (%)
In this clinic 0 (0%) 2 (6%) 9 (10%) 3 (19%) 6 (55%) 24 (48%) 23 (51%) 67 (26%)
Same facility 3 (18%) 6 (17%) 11 (13%) 4 (25%) 3 (27%) 11 (22%) 17 (38%) 55 (21%)
Only offsite 14 (82%) 18 (50%) 32 (37%) 7 (44%) 2 (18%) 14 (28%) 5 (11%) 92 (35%)
Not available 0 (0%) 10 (28%) 35 (40%) 2 (12%) 0 (0%) 1 (2%) 0 (0%) 48 (18%)
TB diagnosis (GeneXpert MTB/RIF™), n (%)
In this clinic 0 (0%) 3 (8%) 10 (11%) 1 (6%) 3 (27%) 19 (40%) 16 (36%) 52 (20%)
Same facility 1 (6%) 8 (22%) 18 (21%) 2 (12%) 2 (18%) 9 (19%) 12 (27%) 52 (20%)
Only offsite 13 (76%) 14 (39%) 20 (23%) 5 (31%) 1 (9%) 16 (33%) 8 (18%) 77 (30%)
Not available 3 (18%) 11 (31%) 39 (45%) 8 (50%) 5 (45%) 4 (8%) 8 (18%) 78 (30%)
Missing 0 0 0 0 0 2 1 3
TB drug resistance testing 2 (12%) 4 (11%) 10 (11%) 0 (0%) 8 (73%) 34 (68%) 30 (67%) 88 (33%)
Cryptococcal meningitis screening/diagnosis
Serum cryptococcal antigen 4 (24%) 11 (31%) 19 (22%) 2 (12%) 7 (64%) 39 (78%) 41 (91%) 123 (47%)
Lateral flow assay 0 (0%) 6 (17%) 15 (17%) 1 (6%) 5 (45%) 24 (48%) 24 (53%) 75 (29%)
CSF India ink and/or CSF cryptococcal
antigen
6 (35%) 5 (14%) 17 (20%) 2 (12%) 9 (82%) 37 (74%) 34 (76%) 110 (42%)
Percentages are computed using the number of sites with a non-missing value.
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Finally, early OI diagnosis is important to decrease the
significant mortality associated with TB and cryptococcal
meningitis in HIV-infected patients [14,45–47]. We found
that TB diagnosis is largely dependent on AFB sputum
smear and culture, which require an intact supply chain
and skilled laboratory technicians. GeneXpert MTB/RIF
was rarely available despite the WHO recommendation
for use as an initial diagnostic test in adults or children
presumed to have HIV-associated TB [48]. This reflects
results from prior studies that found GeneXpert MTB/
RIF™ was generally not available and rarely used in
resource-constrained settings [49,50]. In the case of cryp-
tococcal meningitis screening and diagnosis, neither tra-
ditional serum nor CSF antigen testing are widely
available in resource-limited settings, and the cryptococ-
cal lateral flow assay is rarely available. Efforts to expand
access to point-of-care testing modalities can aid in more
rapid diagnosis and treatment, thereby decreasing
patient morbidity and mortality as well as the spread of
disease.
Table 9. Trends in the comprehensiveness of services for HIV care and treatment sites participating in the
2009 and 2014 survey, IeDEA global consortium (N = 55)
2009
mean (SD)
2014
mean (SD)
Difference
mean (SD) p-Value
All regions 5.7 (1.1) 6.5 (0.7) 0.9 (1.2) <0.001
Region 0.35
Central Africa 5.8 (1.0) 5.8 (1.0) 0.0 (1.4)
East Africa 6.0 (0.9) 6.9 (0.3) 0.9 (1.0)
West Africa 5.8 (1.3) 6.2 (1.0) 0.5 (1.5)
CCASAnet 4.8 (1.7) 6.0 (0.8) 1.2 (1.0)
Asia-Pacific 5.2 (1.1) 6.4 (0.8) 1.2 (1.1)
North America 5.0 (N/A) 7.0 (N/A) 2.0 (N/A)
Site location 0.92
Mostly rural 6.0 (0.0) 7.0 (0.0) 1.0 (0.0)
Mostly urban 5.8 (0.9) 6.8 (0.5) 1.0 (1.2)
Rural 6.4 (0.5) 7.0 (0.0) 0.6 (0.5)
Urban 5.4 (1.2) 6.4 (0.8) 0.9 (1.3)
Type of facility 0.39
Private 5.8 (1.2) 6.3 (0.8) 0.5 (1.0)
Public 5.6 (1.1) 6.6 (0.7) 0.9 (1.2)
Level facility 0.63
Primary 5.7 (1.2) 6.8 (0.6) 1.1 (1.2)
Secondary 5.9 (0.9) 6.9 (0.3) 1.0 (0.8)
Tertiary 5.5 (1.2) 6.2 (0.9) 0.7 (1.4)
Academic affiliation 0.36
No 5.8 (0.9) 6.5 (0.8) 0.7 (1.1)
Yes 5.5 (1.2) 6.5 (0.7) 1.0 (1.2)
Type of patients 0.14
Adults only 4.8 (1.1) 6.1 (0.8) 1.3 (1.4)
Adults and children 6.0 (0.9) 6.7 (0.6) 0.8 (1.0)
PEPFAR country (2014) 0.086
No PEPFAR 4.9 (1.1) 6.2 (0.9) 1.3 (1.4)
PEPFAR 6.0 (1.0) 6.7 (0.6) 0.7 (1.1)
UN Health Development Index 0.036
UN HDI low rank 6.0 (1.0) 6.6 (0.7) 0.7 (1.2)
UN HDI middle rank 5.5 (1.3) 6.0 (0.8) 0.5 (0.6)
UN HDI high rank 4.9 (1.0) 6.4 (0.8) 1.6 (1.0)
The first p-value is a paired Wilcoxon test, and the remaining p-values are the result from a one-way ANOVA F-test
of site-level difference in comprehensiveness from site assessment 1.0 to 2.0.
All summaries are mean (standard deviation [SD]). If SD is N/A then there was only one observation in this category.
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There are limitations of this study in regards to the compre-
hensiveness score itself and in the analysis of 2014 site char-
acteristics and comprehensiveness. First, the
comprehensiveness score weights all services equally, consis-
tent with WHO recommendations. Additionally, the score
assumes that the IeDEA site is the only place patients seek
care, which may cause underestimation of the level of services
patients are actually receiving, Datawere obtained through self-
report by clinical staff at each facility, with limited means for
investigators to verify responses. Thus, under- or over-report of
the availability of services or their receipt, uptake, or quality is
possible. Additionally, we did not have the data to assess impact
of Global Fund support on comprehensiveness, which should be
investigated in future studies as it likely provides themajority of
HIV funding at some sites. Finally, HIV care clinics in the IeDEA
consortium likely represent higher functioning sites within their
regions, so our results may overestimate the background level
of services available at HIV treatment sites.
There are also limitations in the comparative analysis
between SA 1.0 and SA 2.0. The specific questions asked
on the 2009 and 2014 surveys differed slightly, though
not enough to preclude a meaningful comparison. Also,
the number of sites with the data necessary to partici-
pate in the comparison analysis was small relative to the
entire IeDEA network (10%) and the Southern Africa
region was excluded from this analysis, decreasing repre-
sentativeness. The limited sample size also inhibited the
ability to conduct adjusted analyses.
Conclusions
Data from this global survey describe the evolution of HIV
treatment sites in light of changes in treatment recom-
mendations and availability of new diagnostic modalities.
Notably, availability of laboratory testing for drug resis-
tance, toxicity monitoring, OI diagnosis, and NCD screen-
ing is lacking in these settings and could impact patient
outcomes. This gap must be addressed to successfully care
for the growing number of patients living and aging
with HIV.
Overall, there has been an increase in the comprehen-
siveness of services provided since 2009. These site-level
data will be an important component in analyses
addressing HIV patient outcomes. It is difficult to assess
the impact of the current trend towards increased country
ownership of HIV care and treatment sites at this time.
Future site assessment surveys will help elucidate whether
this transition will impact the comprehensiveness of ser-
vices provided in low-resource settings.
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Fred Nalugoda, Francis Wasswa. Infectious Diseases Institute- Kampala,
Uganda: Barbara Castelnuovo, John Matovu, Noela Owarwo. Masaka
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Michael Hobbins. Zambia: Michael Vinikoor, Benjamin Chi. SolidarMed
Lesotho: Christiane Fritz. Malawi: Sam Phiri, Kennedy Malisita. Newlands
Zimbabwe: Cleophas Chimbetete, Maureen Wellington. SolidarMed
Zimbabwe: Kamelia Kamenova.
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Guinea: David Leuenberger, Jean Hebelamou. Senegal: Haby Signate Sy, Aïda
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Kwaghe, Lamda Ramnap, Benson Okwara, Philip Osakede.
Funding
Research reported in this publication was supported by the National Institute
of Allergy and Infectious Diseases (NIAID), the National Institute of Child
Health and Human Development (NICHD) and the National Cancer Institute
(NCI) of the US National Institutes of Health under the following award
numbers: Caribbean, Central, and South America: U01AI069923; Asia-
Pacific: U01AI069907; Central Africa: U01A096299; East Africa:
U01AI069911; Southern Africa: U01AI069924; West Africa: U01AI069919;
and NA-ACCORD: U01AI069918. NA-ACCORD contribution to this work was
also supported by grants U01-DA036935, UL1-TR000083, K24-AI065298, K24-
DA00432, KL2 TR000421, N02-CP55504, P30-AI27757, P30-AI27767, P30-
AI036219, P30-AI50410, P30-AI54999, P30-AI094189, R01-AA16893, R01-
DA11602 R24-AI067039. IeDEA Asia-Pacific received additional funding
from the Dutch Ministry of Foreign Affairs through a partnership with
Stichting AIDS Fonds, and from the Australian Government Department of
Health and Ageing. REDCap support was provided through Vanderbilt
University and UL1 TR000445 from NCATS/NIH.
Disclaimer
The content is solely the responsibility of the authors and does not necessa-
rily represent the official views of the National Institutes of Health.
References
1. WHO. Estimated numbers of people receiving antiretroviral therapy
globally and by WHO region and percentage coverage globally, 2000–2015.
2016. [cited 2016 March 19]. Available from: http://www.who.int/hiv/data/
art_2003_2015.png?ua=1
2. Nash D, Elul B, Rabkin M, Tun M, Saito S, Becker M, et al. Strategies for
more effective monitoring and evaluation systems in HIV programmatic
scale-up in resource-limited settings: implications for health systems
strengthening. J Acquir Immune Defic Syndr. 2009;52(S1):S58–S62.
DOI:10.1097/QAI.0b013e3181bbcc45
Fritz CQ et al. Journal of the International AIDS Society 2017, 20:20933
http://www.jiasociety.org/index.php/jias/article/view/20933 | http://dx.doi.org/10.7448/IAS.20.1.20933
12
3. Adjorlolo-Johnson G, Wahl Uheling A, Ramachandran S, Strasser S,
Kouakou J, Tindyebwa D, et al. Scaling up pediatric HIV care and treatment
in Africa: clinical site characteristics associated with favorable service utiliza-
tion. J Acquir Immune Defic Syndr. 2013;62(1):e7–e13. DOI:10.1097/
QAI.0b013e3182706401
4. Elul B, Basinga P, Nuwagaba-Biribonwoha H, Saito S, Horowitz D, Nash
D, et al. High levels of adherence and viral suppression in a nationally
representative sample of HIV-infected adults on antiretroviral therapy for
6, 12 and 18 months in Rwanda. PLoS One. 2013;8(1):e53586. DOI:10.1371/
journal.pone.0053586
5. Lahuerta M, Lima J, Nuwagaba-Biribonwoha H, Okamura M, Alvim MF,
Fernandes R, et al. Factors associated with late antiretroviral therapy initia-
tion among adults in Mozambique. PLoS One. 2012;7(5):e37125.
DOI:10.1371/journal.pone.0037125
6. Lamb MR, El-Sadr WM, Geng E, Nash D. Association of adherence
support and outreach services with total attrition, loss to follow-up, and
death among ART patients in sub-Saharan Africa. PLoS One. 2012;7(6):
e38443. DOI:10.1371/journal.pone.0038443
7. Leroy V, Malateste K, Rabie H, Lumbiganon P, Ayaya S, Dicko F, et al.
Outcomes of antiretroviral therapy in children in Asia and Africa: a compara-
tive analysis of the IeDEA pediatric multiregional collaboration. J Acquir
Immune Defic Syndr. 2013;62(2):208–219. DOI:10.1097/
QAI.0b013e31827b70bf
8. Nash D, Wu Y, Elul B, Hoos D, Sadr WE; ICAP. Program-level and
contextual-level determinants of low-median CD4+ cell count in cohorts of
persons initiating ART in eight sub- Saharan African countries. Aids. 2011;25
(12):1523–1533. DOI:10.1097/QAD.0b013e32834811b2
9. Vermund SH. Testing and linkage of patients to early care. Aids. 2011;25
(12):1547–1548. DOI:10.1097/QAD.0b013e32834940b3
10. Rebeiro P, Althoff KN, Buchacz K, Gill J, Horberg M, Krentz H, et al.;
North American AIDS Cohort Collaboration on Research and Design.
Retention among North American HIV-infected persons in clinical care,
2000–2008. J Acquir Immune Defic Syndr. 2013;62(3):256–262.
DOI:10.1097/QAI.0b013e31827f578a
11. Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, Jacobson LP,
et al. Trends and disparities in antiretroviral therapy initiation and virologic
suppression among newly treatment-eligible HIV-infected individuals in
North America, 2001–2009. Clin Infect Dis. 2013;56(8):1174–1182.
DOI:10.1093/cid/cit003
12. WHO. Priority interventions: HIV/AIDS prevention, treatment and care
in the health sector (2010 version) [Internet]. WHO Press; 2010. [cited 2014
Aug 3]. Available from: http://whqlibdoc.who.int/publications/2010/
9789241500234_eng.pdf
13. Duda SN, Farr AM, Lindegren ML, Blevins M, Wester CW, Wools-
Kaloustian K, et al. Characteristics and comprehensiveness of adult HIV
care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the
Americas: results of a site assessment conducted by the international epi-
demiologic databases to evaluate AIDS (IeDEA) collaboration. J Int AIDS Soc.
2014;17:19045.
14. WHO. Consolidated guidelines on the use of antiretroviral drugs for
treating and preventing HIV infection-recommendations for a public health
approach. Geneva: WHO Press; 2013.
15. Steingart K, Schiller I, Horne D, Pai M, Boehme C, Dendukuri N. Xpert®
MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
(review). Cochrane Database Syst Rev. 2014;21:CD009593. DOI:10.1002/
14651858.
16. Nicol M, Workman L, Isaacs W, Munro J, Black F, Eley B, et al.
Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary
tuberculosis in children admitted to hospital in Cape Town, South
Africa: a descriptive study. Lancet Infect Dis. 2011;11:819–824.
DOI:10.1016/S1473-3099(11)70167-0
17. Boehme C, Nicol M, Nabeta P, Michael J, Gotuzzo E, Tahirli R, et al.
Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the
Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a
multicentre implementation study. Lancet. 2011;377:1495–1505.
DOI:10.1016/S0140-6736(11)60438-8
18. Boulware DR, Rolfes MA, Rajasingham R, Von Hohenberg M, Qin Z,
Taseera K, et al. Multisite validation of cryptococcal antigen lateral flow
assay and quantification by laser thermal contrast. Emerg Infect Dis.
2014;20(1):45–53. DOI:10.3201/eid2001.130906
19. Kabanda T, Siedner MJ, Klausner JD, Muzoora C, Boulware DR. Point-of-
care diagnosis and prognostication of cryptococcal meningitis with the cryp-
tococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis.
2014;58(1):113–116. DOI:10.1093/cid/cit641
20. Magambo KA, Kalluvya SE, Kapoor SW, Seni J, Chofle AA, Fitzgerald DW,
et al. Utility of urine and serum lateral flow assays to determine the
prevalence and predictors of cryptococcal antigenemia in HIV-positive out-
patients beginning antiretroviral therapy in Mwanza, Tanzania. J Int AIDS Soc.
2014;17:19040. DOI:10.7448/IAS.17.1.19040
21. Pannus P, Fajardo E, Metcalf C, Coulborn RM, Durán LT, Bygrave H, et al.
Pooled HIV-1 viral load testing using dried blood spots to reduce the cost of
monitoring antiretroviral treatment in a resource-limited setting. J Acquir
Immune Defic Syndr. 2013;64:134–137. DOI:10.1097/QAI.0b013e3182a61e63
22. Roberts T, Bygrave H, Fajardo E, Ford N. Challenges and opportunities
for the implementation of virological testing in resource-limited settings. J
Int AIDS Soc. 2012;15:1–7. DOI:10.7448/IAS.15.2.17324
23. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, et al.
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future
prospects for a point-of-care test. Lancet Infect Dis. 2013;13:349–361.
DOI:10.1016/S1473-3099(13)70008-2
24. PEPFAR. The U.S. president’s emergency plan for AIDS relief: five-year
strategy. Executive summary of PEPFAR’s strategy. 2009. [cited 2014 Sep 10].
Available from: http://www.pepfar.gov/about/strategy/document/133244.htm
25. PEPFAR. Congressional budget justification supplement: fiscal year 2014.
Washington (DC): Office of the U.S. Global AIDS Coordinator and Health
Diplomacy; 2014.
26. McGowan CC, Cahn P, Gotuzzo E, Padgett D, Pape JW, Wolff M, et al.
Cohort profile: Caribbean, Central and South America Network for HIV
research (CCASAnet) collaboration within the International Epidemiologic
Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol. 2007;36
(5):969–976. DOI:10.1093/ije/dym073
27. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P,
et al. Cohort profile: the international epidemiological databases to evaluate
AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol. 2012;41(5):1256–1264.
DOI:10.1093/ije/dyr080
28. Gange SJ, Kitahata M, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, et al.
Cohort profile: the North American AIDS cohort collaboration on research
and design (NA-ACCORD). Int J Epidemiol. 2007;36(2):294–301. DOI:10.1093/
ije/dyl286
29. Dabis F, Balestre E, Braitstein P, Miotti P, Brinkhof WGM, Schneider M,
et al. Cohort profile: antiretroviral therapy in lower income countries (ART-
LINC): international collaboration of treatment cohorts. Int J Epidemiol.
2005;34(5):979–986.
30. Divaris K, Newman J, Hemingway-Foday J, Akam W, Balimba A,
Dusenga-Mungu C, et al. Adult HIV care resources, management practices
and patient characteristics in the phase 1 IeDEA Central Africa cohort. J Int
AIDS Soc. 2012;15(2):17422. DOI:10.7448/IAS.15.2.17422
31. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (REDCap) – a metadata-driven methodology and
workflow process for providing translational research informatics support. J
Biomed Inform. 2009;42(2):377–381. DOI:10.1016/j.jbi.2008.08.010
32. International human development indicator-UNDP [Internet]. [cited
2015 Aug 16]. Available from: http://hdr.undp.org/en/data
33. Layer EH, Kennedy CE, Beckham SW, Mbwambo JK, Likindikoki S, Davis
WW, et al. Multi-level factors affecting entry into and engagement in the HIV
continuum of care in Iringa, Tanzania. PLoS One. 2014;9(8):e104961.
DOI:10.1371/journal.pone.0104961
34. Schwitters A, Lederer P, Zilversmit L, Gudo PS, Ramiro I, Cumba L, et al.
Barriers to health care in rural Mozambique: a rapid ethnographic assess-
ment of planned mobile health clinics for ART. Glob Health Sci Pract. 2015;3
(1):109–116. DOI:10.9745/GHSP-D-14-00145
35. Charurat M, Oyegunle M, Benjamin R, Habib A, Eze E, Ele P, et al.
Patient retention and adherence to antiretrovirals in a large antiretroviral
therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One.
2010;5(5):e10584. DOI:10.1371/journal.pone.0010584
36. Roberts T, Bygrave H, Fajardo E, Ford N. Challenges and opportunities
for the implementation of virological testing in resource-limited settings. J
Int AIDS Soc. 2012;15(2):17324. DOI:10.7448/IAS.15.2.17324
37. UNAIDS. Speed up scale-up: strategies, tools and policies to get the best
HIV treatment tomore people sooner. Geneva: Médecins Sans Frontières; 2012.
Fritz CQ et al. Journal of the International AIDS Society 2017, 20:20933
http://www.jiasociety.org/index.php/jias/article/view/20933 | http://dx.doi.org/10.7448/IAS.20.1.20933
13
38. Bonner K, Siemieniuk RA, Boozary A, Roberts T, Fajardo E, Cohn J.
Expanding access to HIV viral load testing: a systematic review of RNA stability
in EDTA tubes and PPT beyond current time and temperature thresholds. PLoS
One. 2014;9(12):e113813. DOI:10.1371/journal.pone.0113813
39. Bonner K, Mezochow A, Roberts T, Ford N, Cohn J. Viral load monitoring
as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic
Syndr. 2013;64(1):74–78. DOI:10.1097/QAI.0b013e31829f05ac
40. Dillon DG, Gurdasani D, Riha J, Ekoru K, Asiki G, Mayanja BN, et al.
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa:
a systematic review and meta-analysis. Int J Epidemiol. 2013;42(6):1754–
1771. DOI:10.1093/ije/dyt198
41. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al.
Incidence and risk factors for new-onset diabetes in HIV-infected patients:
the data collection on adverse events of anti-HIV drugs (D:A:D) study.
Diabetes Care. 2008;31(6):1224–1229. DOI:10.2337/dc07-2013
42. Lang S, Boccara F, Mary-Krause M, Cohen A. Epidemiology of coronary
heart disease in HIV-infected versus uninfected individuals in developed coun-
tries. Arch Cardiovasc Dis. 2015;108:206–215. DOI:10.1016/j.acvd.2015.01.004
43. Hunter D, Reddy K. Gloabl health-noncommunicable diseases. N Engl J
Med. 2013;369:1336–1343. DOI:10.1056/NEJMra1109345
44. Petersen M, Yiannoutsos CT, Justice A, Egger M. Observational research
on NCDs in HIV-positive populations: conceptual and methodological
considerations. J Acquir Immune Defic Syndr. 2014;67(Suppl 1):S8–S16.
DOI:10.1097/QAI.0000000000000253
45. WHO. TB/HIV facts. 2013. [cited 2015 Mar 3]. Available from: http://www.
who.int/tb/challenges/hiv/
46. Koenig SP, Riviere C, Leger P, Joseph P, Severe P, Parker K, et al. High
mortality among patients with AIDS who received a diagnosis of tuberculosis
in the first 3 months of antiretroviral therapy. Clin Infect Dis. 2009;48
(6):829–831. DOI:10.1086/597098
47. Lawn SD, Harries AD, Anglaret X, Myer L,Wood R. Early mortality among
adults accessing antiretroviral treatment programmes in sub-Saharan Africa.
Aids. 2008;22(15):1897–1908. DOI:10.1097/QAD.0b013e32830007cd
48. WHO. Policy update: xpert MTB/RIF assay for the diagnosis of pulmon-
ary and extrapulmonary TB in adults and children. Geneva: WHO Press;
2013.
49. Lukas Fenner MB, Graber C, Nhandu V, Dusingize JC, Cortes CP,
Carriquiry G, et al. Tuberculosis in antiretroviral treatment programs in
lower income countries: availability and use of diagnostics and screening.
PLoS One. 2013;8(10):1–10.
50. Saito S, Howard AA, Reid MJA, Elul B, Scardigli A, Verkuijl S, et al. TB
diagnostic capacity in sub-Saharan African HIV care settings. J Acquir
Immune Defic Syndr. 2012;61(2):216–220. DOI:10.1097/
QAI.0b013e3182638ec7
Fritz CQ et al. Journal of the International AIDS Society 2017, 20:20933
http://www.jiasociety.org/index.php/jias/article/view/20933 | http://dx.doi.org/10.7448/IAS.20.1.20933
14
